The current study preliminarily shows that the combined therapy of apatinib and temozolomide (1) has a promising efficacy, which could be better than that of temozolomide alone, especially for the patients with unmethylated MGMT and wild-type IDH; (2) does not reduce the sensitivity of tumor to bevacizumab; (3) has manageable toxicities; (4) is orally administered without the need for hospital admission. This evidence concerns the gene MGMT and neoplasm.